Replimune Group (REPL) drew fresh attention after the FDA granted accelerated approval for TUDRIQEV in combination with nivolumab in advanced cutaneous melanoma, supported by Phase 2 data and followed by commercialization-focused updates.

The share price reaction around the TUDRIQEV approval has been sharp, with a 30 day share price return of 46.33% and a 90 day share price return of 218.51%. The 1 year total shareholder return of 180.86% sits against weaker 3 and 5 year total shareholder returns, hinting that momentum has recently picked up as investors reassess Replimune Group in light of the FDA decision, follow on equity raise, earnings update and new commercial leadership.

If this type of biotech re rating has caught your eye, it could be a good moment to see which other healthcare stocks using AI are on investors’ radar through the 41 healthcare AI stocks

Bulls argue Replimune Group’s sharp rerating reflects genuine value in TUDRIQEV and a clearer commercial path. Bears point to ongoing losses, legal overhangs and dilution. Which side does the current valuation lean toward?

Price to Book of 13.4x for Replimune Group: Is It Justified?

Replimune Group currently trades at a P/B ratio of 13.4x, which sits well above both the US Biotechs industry and its closest peers. For a stock at $14.97 with no meaningful revenue reported and ongoing losses of $297.0m, that is a rich valuation benchmark for investors to weigh against the recent share price surge.

The P/B ratio compares the company’s market value to its net assets on the balance sheet. For a clinical stage biotech like Replimune Group, which is still unprofitable and focused on R&D rather than generating commercial revenue, a high P/B can often reflect expectations that future assets such as approved therapies and cash flows will justify paying a premium to today’s book value.

Here, the 13.4x P/B stands out against the US Biotechs industry average of 2.4x and a peer average of 3.8x. That is a substantial gap, which suggests the market is assigning Replimune Group a much higher implied value per dollar of net assets than many comparable companies. With analysts also not in tight agreement on price targets, this premium P/B level leaves little room for investors to ignore how quickly the company can move from loss making to meaningful revenue generation.

Result: Price-to-Book of 13.4x (OVERVALUED)

However, investors still face clear risks if Replimune Group’s commercialization ramp for TUDRIQEV disappoints, or if further equity raises dilute existing shareholders again.

Another View on Replimune Group’s Value

The earlier focus on Replimune Group’s 13.4x P/B multiple paints the stock as expensive compared with the US Biotechs industry and peers. Yet the SWS DCF model points in the opposite direction, with an estimated future cash flow value of $87.54 versus a current share price of $14.97, which screens as heavily undervalued.

This creates a wide gap between what the balance sheet suggests and what long term cash flow estimates imply. It leaves investors weighing which lens feels more realistic for a clinical stage biotech that is still unprofitable and forecast to remain so over the next 3 years. Which signal carries more weight for you right now?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Replimune Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mixed signals around Replimune Group have left you undecided, this is a good moment to review the data yourself and form a clear stance. To see both sides of the story in one place, start with the 2 key rewards and 5 important warning signs.

Looking for more investment ideas beyond Replimune Group?

Do not stop with Replimune Group. Use this momentum to scan wider opportunities so you are not relying on a single stock for your next move.

• Target resilient companies with fewer surprises by checking out 80 resilient stocks with low risk scores to see options that may better suit a steadier approach to equity investing.
• Spot potential bargains that combine quality and pricing appeal by reviewing the 52 high quality undervalued stocks before the rest of the market catches up.
• Unearth lesser known opportunities with solid fundamentals through the screener containing 19 high quality undiscovered gems and avoid missing stocks that are still off most investors’ radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.